OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Editorial Board	105
Editorial Board	82
Editorial Board	79
Surgery for prolactinoma	72
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	69
Thiazide-induced hyponatremia	67
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	59
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	58
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	46
The role of androgens in transgender medicine	44
Sexual health and contraception in the menopause journey	42
Coronavirus disease 2019 and vitamin D	39
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	39
Editorial Board	37
Haematological actions of androgens	36
Impulse control disorders and dopamine agonists	36
Editorial Board	34
Cardiometabolic outcomes of early onset hypogonadism in males	34
Remnant lipoprotein particles and cardiovascular disease risk	29
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	28
Editorial Board	27
Metabolic complications and their mechanisms in patients with craniopharyngioma	27
Radioiodine therapy in the different stages of differentiated thyroid cancer	27
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	26
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	26

Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	25
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	25
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	25
Non-oestrogen-based and complementary therapies for menopause	24
Medullary thyroid cancer - An update	23
Pathophysiology of thyroid-associated orbitopathy	23
Approach to patients with elevated low-density lipoprotein cholesterol levels	23
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	22
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	22
Editorial Board	22
Editorial Board	21
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	21
Localization in primary hyperparathyroidism	20
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	20
Safety of androgen therapy in men with prostate cancer	20
Hyponatraemic encephalopathy	20
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	19
Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective	19
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	19
Genotype-phenotype correlations in Graves’ disease	19
Editorial Board	19
Editorial Board	18
Diagnostic algorithm of hyponatremia	18
Type 5 diabetes: A disorder associated with undernutrition: The epidemiology, pathogenesis, clinical features and differential diagnosis	17
Multiple endocrine neoplasia type 2: From molecular genetics to precision therapy	17
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment	17
Mortality in craniopharyngiomas: Data from the last two decades	17
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	16
Preface	16
Diagnosis and treatment of hypernatremia	16
Care quality improvement in differences of sex development	16
COVID-induced thyroid autoimmunity	15
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	15
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	15
Chemokines in thyroid autoimmunity	14
Editorial Board	14
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	14
Anaplastic thyroid cancer: An update	14
Hormone replacement in disorders of sex development, and long-term effects	14
Genetic endocrine tumours focusing on pituitary tumours	13
Preface	13
Outcomes of pregnancies complicated by type 2 diabetes	13
Best practice & research clinical endocrinology & metabolism prolactinoma	13
Ectopic craniopharyngiomas	13
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	12
Editorial Board	12
Addressing the social determinants of adverse outcomes in pregestational diabetes	12
Strategies for improving the knowledge of patients and carers	12
Covid-19 and endocrinology	12
The epidemiology of disorders of sex development	12

Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	12
New potential treatment options for syndrome of inappropriate antidiuresis	11
Nutritional advice for patients with obesity and prediabetes	11
SARS-CoV-2 infection and its effects on the endocrine system	11
Surgical treatment of thyroid cancer: Established and novel approaches	11
Hypopituitarism in patients with prolactinomas: a narrative review	11
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	11
Quality of life in thyroid cancer	11
Editorial Board	11
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	11
How best to monitor the specific side effects of medical treatments of Cushing’s disease	11
Management of patients with statin intolerance	10
Androgen-based therapies in women	10
Current medical treatment and perspective in gonadotroph tumors	10
Long-term thionamide antithyroid treatment of Graves' disease	10
Adolescent primary hyperparathyroidism	10
Editorial Board	9
Type 2 diabetes and obesity in South Asian patients with polyendocrine metabolic ovarian syndrome: The emerging role of metabolomics	9
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	9
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	9
Treatment of chronic hyponatremia and controversy about osmotic demyelination syndrome	9
Real-world value of cabergoline in the treatment of acromegaly	9
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	8
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	8
Burosumab: Current status and future prospects	8
Stress and the interaction of the hypothalamic–pituitary–adrenal axis with other pituitary axes and its consequences on muscle mass	8
COVID-19 vaccination and thyroiditis	8
Preface	8
Pituitary and SARS CoV-2: An unremitting conundrum	7
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	7
Inherited fibroblast growth factor 23 excess	7
Androgens part 2: Emerging areas	7
Vitamin D deficiency or resistance and hypophosphatemia	7
Hyponatraemia and cancer	7
Novel androgen therapies including selective androgen receptor modulators	7
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	7
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	6
Fertility and pregnancy in patients with prolactinoma	6
Resistant prolactinomas	6
Thyroid hormones as permissive regulators of skeletal muscle protein accretion and oxidative capacity: Implications for resistance and endurance training	6
New advances in menopause symptom management	6
Sexual dysfunction in patients with Type 2 diabetes: A South Asian perspective	6
Traumatic brain injury and hypopituitarism	6
Diagnosis and evaluation of sarcopenic obesity	6
Hypothalamus-sparing surgery in craniopharyngiomas: Oncological and hypothalamic long-term outcomes	6
Innovative therapeutics in acromegaly	6
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	6
Heritable hyperparathyroidism: Genetic insights and clinical implications	6
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	6
Control of muscle mass and accretion	6
Tumor-induced osteomalacia: An overview	6
Pituitary dysfunction due to sports injuries	5
Diagnosis of gestational diabetes: Evidence and pitfalls	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Editorial Board	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
Broader impact and outcome of human NR5A1/SF1 variants	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas	4
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Premature ovarian insufficiency, early menopause, and induced menopause	4
Editorial Board	4
Current views on the role of HIF-2α in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma	4
Primary hyperparathyroidism	4
Editorial Board	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
Congenital primary hyperparathyroidism	4
Best practice and research, clinical endocrinology and metabolism preface to the special issue: Diagnosis and treatment of acromegaly acromegaly, a paradigmatic disease second part: Treatment	4
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4
The pathophysiology of hypophosphatemia	4
Pathophysiology and aetiologies of hypernatremia	4
Editorial Board	4